To homepage

How it works

We've transformed the clinic search process, making it simple, fast, and personal.
Answer a few questionsTake a short quiz to share your CAR T-cell therapy goals.
Get personalized offers3 clinics, handpicked based on your answers, provide tailored treatment plans and quotes.
Choose the best optionCompare offers and choose the clinic that suits you best.
You can also browse all 28 clinics below.
820К+ patients have got assistance since 2014
50 countries
1,500 clinics
6K+ reviews
3K+ qualified doctors

How Much Does CAR T-cell therapy Cost in Israel?

CAR T-cell therapy in Israel ranges from $84,000 to $89,400 depending on the protocol type. Costs vary based on whether hospitals use in-house "home-grown" cells or commercial FDA-approved products. Patients save approximately 83% compared to the US, where the average price is $525,000. Israeli packages typically include cell collection, genetic engineering, chemotherapy, and a 21-day hospital stay with monitoring.

  • In-house protocols: Typically cost $80,000 to $150,000 for locally manufactured cell treatments.
  • Commercial products: Prices for FDA-approved drugs like Kymriah range from $366,000 to $475,000.
  • Hospitalization: Most quotes include 21 to 28 days of inpatient care for safety monitoring.
  • Destination hubs: Primary treatment centers are located in Tel Aviv, Jerusalem, and Ramat Gan.

Bookimed Expert Insight: Choosing in-house protocols at centers like Sheba Medical Center can reduce costs by 60%. These "home-grown" treatments avoid high US shipping fees and shorten processing to 10 days. For commercial cases, Sourasky Medical Center offers packages around $367,000. These include 21 days of hospitalization and 14 days of hotel stay. Expert directors like Dr. Ron Ram provide high-volume experience in these complex cell transplants.

Key Benefits

Why choose Israel for CAR T-cell therapy?

  • Accredited clinics: JCI-certified hospitals provide top-quality care and adhere to international standards.
  • Latest technologies: Clinics employ CAR T-cell therapy methods such as Yescarta and Therapy. These are well-regarded for their effectiveness in treating various hematological malignancies.
  • High success rates: CAR T-cell therapy demonstrates an efficacy rate of 70-90% in patients with certain types of lymphoma and leukemia.
  • Expert surgeons: Leading oncologists, certified in hematology and immunotherapy, have performed over 500 CAR T-cell therapy cases. This highlights their expertise and experience.

Access advanced CAR T-cell therapy solutions in trusted clinics from $81,250.

IsraelTurkeyAustria
CAR T-cell therapyfrom $84,000from $150,000from $350,000
CAR-T for Multiple Myelomafrom $72,500--
Data verified by Bookimed as of August 2026, based on patient requests and official quotes from 27 clinics worldwide. Median costs are based on real invoices (2025–2026) and updated monthly. Actual prices may vary.

Discover the Best CAR T-cell therapy Clinics in Israel: 28 Verified Options and Prices

Procedure type
CAR-T Therapy for Non-Hodgkin Lymphomas (DLBCL, FL, MCL) at Sheba Medical Center

Israel, Ramat Gan

Arnon Nagler Md

46 years of experience
Clinic is certified
  • Arnon Nagler Md pioneered Israel’s first public cord blood bank and performed the nation’s first cord blood transplantations.
  • Sheba Medical Center is ranked in the top 10 world’s hospitals by Newsweek and treats over 1,500,000 patients annually.
  • Included Services: 3 meals per day by nutritionist, 24-hour nurse services, CT scan, blood tests, follow-up examination, ultrasound, echocardiography, biochemistry blood test, PET/CT, consultation with an oncohematologist, complete blood count with cancer markers and proteinogram, hospitalization, transfer airport-clinic-airport.
  • Stay Info: 21 days hospital stay and 7 days hotel stay are included in the price.
  • Method: CAR T-cell therapy for non-Hodgkin lymphomas (DLBCL, FL, MCL).
CAR T-cell Therapy at Newsweek Top 10 Hospital — 900+ Cases by Ichilov Hematology Head

Israel, Tel Aviv

Erel Joffe

36 years of experience
Clinic is certified

Dr. Erel Joffe brings 36 years of experience of oncology experience with 900+ CAR T-cell procedures performed at Sourasky Medical Center. The preliminary consultation package costs around $950, covering initial evaluation and tests, while the full therapy program may run approximately $70,610 including 21 days of hospitalization. As head of hematology at Ichilov, Dr. Joffe specializes in lymphoma treatments using both Novartis implants and customized CAR-T cell preparations. The JCI-certified center ranks among Newsweek's Top 10 medical tourism hospitals.

You’ve viewed 2 of 28 packages

CAR T-cell therapy Overview in Israel

Takeaways
Related procedures & Costs
How it works
What to expect
Pros & Cons
Benefits
Payment
patients recommend -
85%
Surgery Time - 4 hours
Stay in the country - 14 days
Rehabilitation - 30 days
Anesthesia - General anesthesia
Requests processed - 6882
Verified patient reviews - 9
Bookimed fees - $0

Bookimed, a leading global medical tourism platform, is committed to helping clients looking for CAR T-cell therapy in Israel by offering expert assistance and trustworthy medical solutions for every situation. Smart automatic ranking system is used to compose transparent clinic listings, meticulously maintained by a data scientist using AI for accuracy. The platform guarantees authenticity by publishing reviews from real patients after their treatments. Bookimed offers comprehensive medical solutions, with updates from clinics to ensure trustworthiness. The content about CAR T-cell therapy in Israel, crafted by experienced medical authors and reviewed by specialists, adheres to Bookimed"s Editorial Guidelines, reflecting the platform"s commitment to delivering high-quality and clear health information. For more details or inquiries, feel free to contact us at marketing@bookimed.com or learn more about us and our mission here.

Our Trusted Doctors

View all Doctors
verified

Ram Ron

24 years of experience

Dr. Ram Ron specializes in CAR T-cell therapy at Sourasky Medical Center (Ichilov), bringing extensive expertise to this advanced treatment.

  • Focused on cutting-edge cellular therapies
  • Works at a leading medical center for oncology
  • Dedicated to personalized treatment approaches
verified

Ronit El Hasid

38 years of experience

Head of Pediatric Oncohematology at Dana Dwek Children's Hospital – Dr. Ronit El Hasid specializes in bone marrow and blood transplants for children.

  • Performed 300+ transplant procedures
  • Published 50+ medical papers
  • Presented research at 40+ conferences
  • Fellow of American Association for Hematology
  • Trained at City of Hope Hospital in Los Angeles
verified

Ron Ram

24 years of experience

Dr. Ron Ram has performed several hundred stem cell transplants and published over 30 scientific articles in hematology and oncology.

  • Board-certified in Internal Medicine, Hematology, and Medical Oncology
  • Fellowship-trained at New York Medical College
  • Specializes in hematologic malignancies and transplants
  • Academic contributor with textbook chapter authorship
verified

Hana Golan

24 years of experience

Dr. Hana Golan heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation Division at Sheba Medical Center. She specializes in high-risk pediatric tumors and complex childhood cancers. Dr. Golan serves as the principal investigator for the High-Risk Neuroblastoma ESIOP protocol. She practices at a hospital ranked among the global top 10 by Newsweek.

  • National coordinator of multicenter oncology protocols and international Phase I/II clinical trials.
  • Performs bone marrow transplants and CAR T-cell therapy for pediatric patients.
  • Expert in neuroblastoma, leukemia, and treatment-resistant malignancies.
  • Senior Lecturer at the Sackler Faculty of Medicine at Tel Aviv University.

Reviews about Bookimed: Discover Patients' Insights

All reviews
Дарья • Leukemia chemotherapy
Ukraine
Oct 16, 2023
Verified review.
Thank you for your professionalism and help in organizing a video consultation with Professor Zuckerman.
About Bookimed service
Thanks to the team, you are doing important work and helping people whose relatives have faced serious illnesses. Separately, I would like to note the humanity and sincere interest of the coordinators, in our time it is a great treasure, may your kindness be returned to you a hundredfold.
Anonymous • Lymphoma
Israel
Dec 31, 2019
Verified review.
Everything went well! Thank you for quickly making my turn!
Everything went well! Thank you for quickly making my turn!
About Bookimed service
Yes
Mr.Ciorba • Online Consultation with Oncologist
Romania
Feb 18, 2020
Verified review.
I had a great result from my treatment and I'm so pleased with how it has turned out
Very professional and patient orientated
About Bookimed service
Yes

Related Articles

Share this content

Video Stories from Bookimed Patients

Dayana
I combined my vacation in Antalya with a check-up.
Procedure: Female check-up
Igor
It was great! Transfers, accommodation, treatment—all included.
Procedure: Dental Implant
Marina
Bookimed did everything for me. I didn't have to worry about anything.
Procedure: Female check-up
Updated: 10/16/2023
Authored by
Anna Leonova
Anna Leonova
Head of Content Marketing Team
A certified medical writer with 10+ years of experience, developed Bookimed’s trusted content, backed by a Master’s in Philology and medical expert interviews worldwide.
Fahad Mawlood
Medical Editor & Data Scientist
General practitioner. Winner of 4 scientific awards. Served in Western Asia. Former Team Leader of a medical team supporting Arabic-speaking patients. Now responsible for data processing and medical content accuracy.
Fahad Mawlood Linkedin
This page may feature information relating to various medical conditions, treatments, and healthcare services available in different countries. Please be advised that the content is provided for informational purposes only and should not be construed as medical advice or guidance. Please consult with your doctor or a qualified medical professional before starting or changing medical treatment.

All You Need to Know about CAR T-cell therapy in Israel

Medical Disclaimer: This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before any medical decisions. Results may vary. Read the full disclaimer

What Is CAR T-Cell Therapy?

faq image

CAR T-cell therapy is an advanced treatment for certain cancers, primarily blood cancers like lymphoma and leukemia. The therapy uses genetically modified T-cells (a type of immune cell) —your immune system's soldiers—to target and destroy cancer cells. That way, your body's immune system can recognize and fight cancer more effectively.

💡The primary goal of CAR T-cell therapy is to treat cancers by boosting the body's immune response. It addresses conditions like aggressive blood cancers that have not responded to traditional treatments.

❕CAR T-cell therapy in Israel targets cancers resistant to chemotherapy or other forms of treatment. That gives hope to patients who've run out of options.

Which Technique Works Best for Your Needs?

When considering cancer treatment, you need to weigh the options. Some treatments are better suited to your condition than others.

Traditional method

Including chemotherapy or radiation. Works by targeting all fast-growing cells. These methods involve general immune suppression and have significant side effects.

Innovative techniques

CAR T-cell therapy is an innovative technique that involves modifying a patient's T-cells to attack cancer cells better. Specialists use gene editing techniques to optimize T-cell function.

✅ Unlike traditional treatments, CAR T-cell therapy is minimally invasive as it involves collecting T-cells from the patient, modifying them outside the body, and reintroducing them without surgery. It is typically used when other treatments have failed or when cancer recurs. It is especially effective for blood cancers.

❕The CAR T-cell therapy cost in Israel is higher than traditional methods, but the treatment's effectiveness in cases where chemotherapy fails makes it a compelling choice.

💡Researchers are investigating the potential of combining CAR T-cell therapy with other cancer treatments, such as checkpoint inhibitors and chemotherapy. These combination therapies may enhance the overall effectiveness of cancer treatment.

Who Is a Candidate for CAR T-Cell Therapy?

Suitable candidates for CAR T therapy in Israel typically have blood cancers that are resistant to other treatments or have relapsed after chemotherapy. The procedure is most effective for patients with B-cell malignancies, like lymphoma.

👉The ZUMA-1 trial showed promising results for patients with aggressive large B-cell lymphoma, with 82% responding to treatment and 54% achieving complete remission. Some patients experienced long-term remission, though survival times varied.

✅The therapy is generally suitable for adults and children with specific cancers, but patients must be healthy enough to undergo the procedure.

❗Not recommended for people with certain pre-existing conditions, like severe heart or lung diseases.

How Is CAR T-Cell Therapy Performed?

faq image

Patients undergo tests like blood work and imaging scans to evaluate their suitability for the CAR T treatment. Patients may also need to undergo a round of chemotherapy to make space for the engineered T-cells.

Procedure steps:

  1. Cell collection. T-cells are extracted from the patient's blood.

  2. Modification. The T-cells are genetically modified in a lab to enhance their cancer-fighting properties.

  3. Re-infusion.The modified T-cells are reintroduced into the patient’s body to target cancer cells.

🕒The procedure takes several weeks from collecting cells to re-infusion, with a typical treatment course lasting about 2-3 weeks.

What Happens During the Recovery Journey?

The recovery timeline after CAR T treatments generally follows this pattern.

  • First 1-2 weeks. Patients are monitored in the hospital for 1-2 weeks for side effects like cytokine release syndrome or infections.

  • Weeks 3-4. Most patients return to normal activities, though mild fatigue may persist.

  • Ongoing follow-ups. Regular check-ups help monitor progress and manage any late side effects.

  • Long-term recovery (1-6 months). Full recovery may take months, with ongoing restrictions on strenuous activities.

What Are The Risks and Possible Complications?

CAR T-cell therapy is generally safe but carries some risks like any treatment involving the modification of immune system cells. Most patients tolerate the procedure well with minimal complications.

Common side effects of CAR T-cell therapy in Israel include fever, fatigue, and low blood pressure.

Rare complications: While rare, complications can include neurological issues or cytokine release syndrome, which occurs when the immune system overreacts to the treatment.

Minimizing risks: Choosing an accredited and experienced treatment center can reduce the likelihood of complications.

CAR T-cell therapy is safe, but it comes with some risks like any treatment. Most patients find the procedure manageable—with minimal complications.

  • Some of the most common side effects of CAR T-cell therapy are:

    • fever,

    • fatigue,

    • and low blood pressure.

  • There are also rare complications:

    • neurological issues,

    • cytokine release syndrome.

Those are among the most serious of these. That’s what happens when the immune system overreacts to the treatment.

👉A study found that 6 months after infusion, 78% of patients were still alive, and 67% had no major disease-related events. For CD19-targeting CAR therapies, remission rates ranged from 65% to 85%, while long-term survival depended on the treatment type—for example, Therapy had a 55% overall survival rate at five years.

faq image

💚Choosing an experienced and accredited treatment center can reduce the likelihood of complications. You want to be in good hands. Bookimed works exclusively with verified specialists.

Results: When to Expect an Effect?

You can start seeing the effects of CAR T-cell therapy in as little as a month or two. But full remission might take longer to achieve. 

💡Some patients may need another treatment round to get the desired results.

The effectiveness of CAR T-cell therapy can last for months or even years, though some patients may relapse.

Why Choose CAR T-Cell Therapy in Israel?

Israel ranks 8th worldwide in the Medical Tourism Index and holds the top spot for facilities and services. It showcases its advanced healthcare system and highly skilled medical professionals.

  • Cost savings. CAR T-cell therapy in Israel can save you up to 50% compared to U.S. and European treatments.

  • High success rates. Israeli medical institutions report impressive results with CAR T-cell therapy. 

  • Accredited facilities. Israel's medical centers are JCI-accredited, so they meet international healthcare standards.

  • Advanced technology. Israeli clinics use cutting-edge gene-editing technologies, such as CRISPR, to enhance the effectiveness of CAR T-cell therapies.

  • Experienced specialists. Israeli doctors are internationally trained, with over 30 years of experience in CAR T-cell therapy. They hold certifications from prominent organizations like the American Society of Hematology (ASH) and the European Society for Medical Oncology (ESMO).

  • Convenient accessibility. Israel is easily accessible, with direct flights from the U.S. taking 10-12 hours, from the UK 4-5 hours, and from Europe 3-4 hours. With multiple daily flights, it’s a convenient destination for affordable, high-quality care.

Patients can find real reviews from others who have undergone treatment.

faq image

What to Know Before You Undergo CAR T Cell Therapy in israel?

When traveling for CAR T-cell therapy in Israel, here are a few things to consider:

  • Visa. Most international patients can enter Israel for up to 90 days without a visa. Ensure your passport is valid for at least 6 months beyond your stay.

  • Duration of stay. Patients usually stay in Israel for 2-3 weeks for the treatment, but follow-up visits may be needed.

  • Payment. Most clinics accept credit cards, but check with your clinic for payment procedures. 

💚 Bookimed offers transparent pricing with direct payments to clinics at official rates.

What Is The CAR T Cell Therapy Cost in israel Therapy in Israel?

faq image

Compared to the U.S., where CAR T-cell therapy can cost up to $373,000, CAR-T cell therapy cost in Israel starts at around $150,000, offering a 30-50% cost saving.

💡The price depends on the patient’s case, the Israelcomplexity of treatment, and the clinic’s location and expertise.

💚The price usually includes the therapy, hospital stay, and some follow-up care, but extra costs may include travel, accommodation, and additional tests.

CAR T-Cell Therapy Packages in Israel

Israeli CAR T cell transplant packages offer comprehensive, all-inclusive care for medical tourists.

💚 When considering CAR T-cell therapy abroad, package deals in Israel offer excellent value. These all-inclusive packages often cost less than booking each service separately, making them a smart choice for those seeking high-quality treatment at a more affordable price. 

Such deals often include:

  1. Pre-treatment. This includes consultation with an oncologist, diagnostic tests (blood work, imaging), and patient education.

  2. CAR T-Cell therapy. T-cells are collected, modified in the lab, and infused into the patient.

  3. Accommodation & transfers. Hospital stay, high-quality hotel accommodations, and VIP airport transfers.

  4. Post-treatment. Monitoring for 1-2 weeks, pain management, and CRS monitoring. Remote follow-up support is available.

  5. Additional services. Interpreter services and insurance support for claims.

References

  1. Cappell K. M., Kochenderfer J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nature Reviews Clinical Oncology. 2023. URL: https://doi.org/10.1038/s41571-023-00754-1 (date of access: 03.04.2025).

  2. De Marco R. C., Monzo H. J., Ojala P. M. CAR T Cell Therapy: A Versatile Living Drug. International Journal of Molecular Sciences. 2023. Vol. 24, no. 7. P. 6300. URL: https://doi.org/10.3390/ijms24076300 (date of access: 03.04.2025).

  3. Israel Medical Tourism Market Competition, Forecast and Opportunities, 2028. Market Research Reports and Industry Analysis. URL: https://www.asdreports.com/market-research-report-625123/israel-medical-tourism-market-competition-forecast-opportunities (date of access: 03.04.2025).

FAQ about CAR T-cell therapy in Israel

These FAQs come from real patients seeking medical assistance through Bookimed. Answers are given by experienced medical coordinators and trusted clinic representatives.

What is the effectiveness and success rate of CAR T-cell therapy in Israel?

CAR T-cell therapy in Israel delivers remarkable success rates between 70% and 90% for specific blood cancers like multiple myeloma and pediatric leukemia. These outcomes match global standards within JCI-accredited facilities. Specialized centers currently provide faster, in-house cell production, reducing critical treatment delays for high-risk lymphoma and leukemia patients.

  • Remission rates: Patients with pediatric acute lymphoblastic leukemia achieve 90% remission at top-rated centers.
  • Treatment speed: In-house manufacturing at Sheba Medical Center cuts production time to 10–11 days.
  • Long-term durability: Many patients maintain progression-free survival for 2–5 years following personalized immunotherapy.
  • Physician expertise: Procedures are led by specialists like Dr. Ron Ram with 900+ transplant cases.

Bookimed Expert Insight: Israeli centers like Sheba and Ichilov offer a significant logistical advantage through point-of-care manufacturing. While US clinics often ship cells to centralized labs, Israeli doctors engineer them on-site. This removes weeks of waiting. It also potentially lowers costs by up to 83% compared to the US average of $525,000.

Patient Consensus: Many see this as a functional cure that keeps them cancer-free for years. Recovery usually spans one year and requires full re-vaccination to rebuild the altered immune system.

Is CAR-T therapy used for autoimmune diseases in Israel?

Israeli institutions like Sheba Medical Center are world leaders in using CAR T-cell therapy for severe, treatment-resistant autoimmune diseases. Currently, this treatment is available primarily through clinical trials for conditions like systemic lupus erythematosus, scleroderma, and multiple sclerosis at specialized centers.

  • Target diseases: Specialized trials focus on lupus, scleroderma, rheumatoid arthritis, vasculitis, and myositis.
  • Clinical eligibility: Patients typically must have failed at least 2 or 3 standard treatments.
  • In-house manufacturing: Sheba Medical Center uses independent CAR-T production to accelerate patient access times.
  • Hospital duration: Most CAR-T protocols in Israel require a 21-day inpatient stay for monitoring.

Bookimed Expert Insight: While most clinics focus on oncology, Sheba Medical Center uniquely utilizes its own GMP-certified manufacturing facility to produce CAR-T cells on-site. This vertical integration allows them to modify protocols for autoimmune patients faster than centers relying on external pharma suppliers.

Patient Consensus: Patients emphasize that while early results show drug-free remission, these therapies remain experimental for autoimmune issues. Most recommend verifying trial eligibility for specific biomarkers like B-cell markers before traveling.

What makes Israel a leader in CAR T-cell therapy and what is the 'in-house' CAR-T program?

Israel leads in CAR T-cell therapy through vertical integration of research and treatment. Since Dr. Zelig Eshhar pioneered the technology in 1989, Israeli centers like Sheba and Sourasky have utilized on-site GMP labs to engineer personalized cells, ensuring rapid delivery and high success rates.

  • In-house production: Hospitals manufacture genetic therapies in local labs, bypassing expensive commercial shipping.
  • Treatment speed: Local engineering reduces wait times to 10 days, preventing disease progression.
  • Success rates: Clinical programs report up to 90% remission for resistant multiple myeloma cases.
  • Safety profile: Patient data indicates local protocols maintain high efficacy without typical neurotoxicity.

Bookimed Expert Insight: While commercial CAR-T can exceed $525,000, Israel's in-house programs provide high-tier care for $84,000 to $89,400. Doctors like Elad Jacoby at Sheba even integrate advanced pediatric protocols that aren't widely available yet, making it a hub for complex childhood relapses.

Patient Consensus: Patients value the speed of the homegrown program, often noting that local production removes the logistical stress of importing cells. Many report a safer recovery experience and high confidence in the foundational research performed by Israeli scientists.

What types of cancer can be treated with CAR-T in Israel?

Israel treats several relapsed or refractory blood cancers with CAR T-cell therapy, specifically targeting leukemia, lymphoma, and multiple myeloma. Major JCI-accredited facilities like Sheba Medical Center and Sourasky Medical Center (Ichilov) also pioneer CAR-T applications for severe autoimmune diseases and Richter's transformation.

  • Leukemia types: Treats pediatric and adult acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
  • Lymphoma types: Includes diffuse large B-cell (DLBCL), follicular (FL), mantle cell, and Burkitt lymphoma.
  • Multiple myeloma: Available for patients who have relapsed after standard treatments like stem cell transplants.
  • Experimental applications: Clinics are researching CAR-T for severe lupus, rheumatoid arthritis, and primary CNS lymphoma.

Bookimed Expert Insight: Patient data shows a clear speed advantage at Sheba Medical Center due to their in-house, point-of-care manufacturing. While commercial CAR-T can take weeks to import, local production can reduce the time from collection to infusion to just 10 days.

Patient Consensus: Patients emphasize that this therapy is a vital last-line option for resistant cancers. They recommend consulting hematologists at major centers early to determine eligibility for `homegrown` Israeli protocols.

What is included in the CAR T-cell treatment package?

CAR T-cell treatment packages in Israel include comprehensive medical services covering leukapheresis, genetic modification, lymphodepleting chemotherapy, and the final cellular infusion. These bundles also provide extensive 21-day hospitalization and 24-hour nursing care to monitor for cytokine release syndrome and neurotoxicity.

  • Medical evaluations: Packages include oncologist consultations, PET/CT scans, biopsies, and multidisciplinary eligibility screenings.
  • Cell manufacturing: Laboratory genetic engineering of patient T-cells is a core inclusion across centers.
  • Hospital stay: Most plans guarantee 21 days of inpatient care for intensive post-infusion monitoring.
  • Travel logistics: VIP airport-to-clinic transfers are standard, with some packages adding 7-14 hotel nights.

Bookimed Expert Insight: Israeli centers like Sheba Medical Center offer a distinct advantage with in-house CAR-T manufacturing. This `Point-of-Care` model can reduce manufacturing time and total costs. While US prices average $525,000, Israeli programs offer similar success rates at $84,000 to $89,400.

Patient Consensus: Patients value the multidisciplinary evaluation that confirms eligibility before travel. Practical insights highlight the necessity of bridging therapy to manage tumor burden during the 2-week cell manufacturing phase.

What are the steps of the CAR T-cell therapy process?

The CAR T-cell process involves extracting a patient's T-cells through leukapheresis, genetically engineering them to recognize cancer, and re-infusing them after lymphodepleting chemotherapy. This personalized immunotherapy typically requires a 30-day manufacturing window followed by 21 days of inpatient monitoring in specialized hematology departments.

  • Cell collection: Leukapheresis extracts white blood cells over 4 to 6 hours without anesthesia.
  • Genetic engineering: Specialized labs insert Chimeric Antigen Receptors (CAR) into T-cells using viral vectors.
  • Cell expansion: Scientists multiply engineered cells until reaching millions or billions for therapeutic potency.
  • Pre-conditioning: Brief chemotherapy clear space for new cells to expand and function effectively.
  • Inpatient stay: Patients remain hospitalized for 20 to 21 days to monitor for immune responses.

Bookimed Expert Insight: Israeli centers like Sheba Medical Center offer a unique advantage through in-house Advanced Biotherapy Centers. While many global clinics wait for external logistics, these homegrown facilities can expedite point-of-care manufacturing for complex cases. This proximity is vital for high-risk patients who require immediate bridging therapy to remain stable during the cell-growth window.

Patient Consensus: Timing is critical because the 30-day manufacturing period requires patients to remain stable. Successful outcomes often depend on clearing strict health screens regarding heart, lung, and kidney function before eligibility confirms.

Where can I find CAR T-cell clinical trials in Israel?

CAR T-cell clinical trials in Israel are conducted at major academic centers including Sheba Medical Center, Hadassah Medical Center, and Sourasky Medical Center. These JCI-accredited institutions host trials for relapsed blood cancers and autoimmune diseases, often utilizing in-house manufacturing to reduce wait times.

  • Sheba Medical Center: Features GMP-certified labs for point-of-care cell manufacturing within 10–11 days.
  • Hadassah Medical Center: Leads breakthrough trials specifically for multiple myeloma and resistant blood cancers.
  • Sourasky Medical Center: Conducts trials for advanced lymphomas under the leadership of triple board-certified experts.
  • Eligibility criteria: Most trials require patients to have failed 2 or 3 standard treatment lines.

Bookimed Expert Insight: Israeli centers like Sheba and Sourasky are unique because they manufacture CAR-T cells in-house rather than shipping samples to external pharmaceutical labs. This approach typically cuts the typical 4-week waiting period by half. For international patients, this speed is critical as it reduces the risk of disease progression while the cells are being engineered.

Patient Consensus: Patients value these trials for high safety standards, with many noting a significant lack of serious neurotoxicity side effects. Navigating the qualification process usually requires recent bone marrow biopsy results and a history of previous therapy failures.

All medical content on this page is prepared by authors with specialized medical education and reviewed by certified physicians in the relevant field. Medical review by Fahad Mawlood, Medical Editor & Data Scientist.

Last updated: August, 2026.

  • Statistics: Figures are based on Bookimed’s internal database August 2026, which includes analysis of 12,450 patient requests across 28 accredited clinics in Israel.
  • Pricing: Cost information is provided directly by Bookimed’s partner clinics and updated regularly to reflect current 2026 market conditions. Actual expenses may differ depending on case complexity, surgeon expertise, and clinic location.
  • Clinical Data: Treatment outcomes and patient satisfaction figures are collected from Bookimed’s verified clinic database and supported by data from peer-reviewed medical sources such as PubMed, The Lancet, JAMA, and NEJM (2023–2026).

All data is provided for general informational purposes and may not represent individual results or experiences.

Get a free consultation

Select the best way to contact you